Tag Archives: Reduction

FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension

FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Print this page DURHAM, N.C.–(BUSINESS WIRE)–Mar. 12, 2019– Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients… Read More »

JAMA findings suggest 'unintended harm' from Hospital Readmissions Reduction Program

Dive Brief: New evidence links CMS’ Hospital Readmissions Reduction Program to unintended harm in some patients, a JAMA editorial suggests.  Researchers analyzed 8.3 million hospitalizations of Medicare enrollees for heart failure, acute myocardial infarction and pneumonia over four periods from April 2005 through March 2015. Thirty-day post-discharge mortality for heart failure patients rose following announcement… Read More »

Part II | MedPAC’s Proposed “Reforms” Should Be Tested Before They’re Implemented: CMS’s Hospital Readmissions Reduction Program Is Exhibit A

By KIP SULLIVAN JD  The Hospital Readmissions Reduction Program (HRRP), one of numerous pay-for-performance (P4P) schemes authorized by the Affordable Care Act, was sprung on the Medicare fee-for-service population on October 1, 2012 without being pre-tested and with no other evidence indicating what it is hospitals are supposed to do to reduce readmissions. Research on the… Read More »